Research funder · Australia
Therapeutic Innovation Australia
- Grants since 2016
- 310
- Awarded, last 5 years (where amounts are published)
- —
- Funded works, last 5 years
- 146
- Funded works, all time
- 282
Grants
2026
Manufacture of autologous T regulatory cells modified ex vivo to express T cell receptors for autoimmune disease
2026
Peripherally Restricted NPSR1 Antagonist in Endometriosis
2026
Human high-throughput in-vitro phenotypic screening for new epilepsy drugs
2026
Pre-clinical development of a novel, patented small molecule to treat COVID-19 respiratory injury
2026
Monitoring the therapeutic efficacy of BD-218, a human neutralising monoclonal antibody against SARS-CoV-2, in COVID-19 patients using Nanostring gene expression analysis
2026
Developing Glutathione transferase Omega 1 inhibitors as anti-inflammatory therapeutics
2026
The druggable transcriptome: Small Molecules inducing Reading Frame Stops (SMIRFS)
2026
Pre-candidate selection for novel schizophrenia therapeutics
2026
Identifying therapeutics for the treatment of advanced BRCA2 breast cancer”
2026
Development of novel cellular cancer therapeutics
2026
Therapeutic possibilities for PYROXD1 myopathy
2026
First-in-Class Dual Inhibitor of Target 1.1 and Target 1.2 for Neuropathic Pain
2026
Novel antitoxin compound discovery for the treatment of antibiotic resistant bacteria
2026
Preclinical ADME and PK drug properties of novel inhibitors of SOX18 transcription factor
2026
NPSR1 Antagonist in Endometriosis
2026
FLVCR2 inhibition for the treatment of glioblastoma
2026
Using patient-derived stem cell models to identify new therapies for NF1 Neurodevelopmental Disorders
2026
Red blood cell-extracellular vesicles to treat retinal degenerative diseases.
2026
Identification of novel immune-checkpoint therapies to inhibit interaction between PD-L1 and CMTM6, a new regulator of anti-tumour immunity
2026
Development of a Continuous Bioprocessing Platform for Antibody Purification from CHO Supernatant
2026
Scale-up of LAT9997 as a treatment for chronic neuropathic pain
2026
Lead discovery for the orphan GPCR, GPR88
2026
Novel gene therapy platforms for hemophilia B
2026
New generation combination therapies for advanced prostate cancer
2026
RAPClot bioassay validation and optimisation
2026
Development of Integrin αVβ3 Agonists to Promote Remyelination in Multiple Sclerosis
2026
Developing a Salmonella combination vaccine for protection against enteric fever and invasive salmonellosis
2026
Development of inhibitors of dengue virus (DENV) NS1 protein dimerization as novel antiviral therapeutics
2026
Development of novel fluorinated ligands of fibroblast activation protein, FAP, as diagnostic radiotracers of oncological disorders
2026
Developing an agonistic antibody
2026
Inhibiting cystogenesis in Polycystic Kidney Disease with AURKA PROTACs
2026
Characterisation of novel antibodies for the treatment of neuropathic pain
2026
Development of anti-virulence strategies to combat MDR gram-negative pathogens
2026
Identification of Inhibitors of a Key Necroptotic Protein Through Fragment Screening
2026
Drugs that block lymphocyte perforin - focused immunosuppressive agents for auto-immune and post-infectious pathologies
2026
The discovery and development of novel antibiotics against MDR and XDR Gram-negative pathogens
2026
Development of a clinical-grade CAMKK2 inhibitor for the treatment of castration-resistant prostate cancer
2026
SAi001 Pharmacokinetic Bridging Study
2026
Surface plasmon resonance-based screening of DNA aptamers targeted to small molecule drugs
2026